|
🐜
|
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
13 auth.
M. Genovese,
K. Kalunian,
J. Gottenberg,
N. Mozaffarian,
B. Bartok,
F. Matzkies,
Jie Gao,
Ying Guo,
Chantal Tasset,
J. Sundy,
...
K. de Vlam,
D. Walker,
T. Takeuchi
|
7 |
2019 |
7
🐜
|
|
🐜
|
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
28 auth.
B. Feagan,
S. Danese,
E. Loftus,
S. Vermeire,
S. Schreiber,
T. Ritter,
R. Fogel,
R. Mehta,
S. Nijhawan,
R. Kempiński,
R. Filip,
I. Hospodarskyy,
U. Seidler,
F. Seibold,
I. Beales,
...
Hyo Jong Kim,
J. McNally,
C. Yun,
Sally Zhao,
Xiaopeng Liu,
C. Hsueh,
Chantal Tasset,
R. Besuyen,
Mamoru Watanabe,
W. Sandborn,
G. Rogler,
T. Hibi,
L. Peyrin-Biroulet
|
7 |
2021 |
7
🐜
|
|
🐜
|
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
11 auth.
R. Westhovens,
P. Taylor,
R. Alten,
D. Pavlova,
F. Enríquez-Sosa,
M. Mazur,
...
M. Greenwald,
A. Van der Aa,
F. Vanhoutte,
Chantal Tasset,
Pille Harrison
|
7 |
2016 |
7
🐜
|
|
🐜
|
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
11 auth.
A. Kavanaugh,
J. Kremer,
L. Ponce,
R. Cseuz,
O. Reshetko,
M. Stanislavchuk,
...
M. Greenwald,
A. Van der Aa,
F. Vanhoutte,
Chantal Tasset,
Pille Harrison
|
7 |
2016 |
7
🐜
|
|
🐜
|
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
16 auth.
D. Heijde,
X. Baraliakos,
L. Gensler,
W. Maksymowych,
V. Tseluyko,
O. Nadashkevich,
W. Abi-Saab,
Chantal Tasset,
L. Meuleners,
R. Besuyen,
...
T. Hendrikx,
N. Mozaffarian,
Ke Liu,
Joy M. Greer,
A. Deodhar,
R. Landewé
|
7 |
2018 |
7
🐜
|
|
🐜
|
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
20 auth.
B. Combe,
A. Kivitz,
Yoshiya Tanaka,
D. M. van der Heijde,
J. A. Simón,
H. Baraf,
U. Kumar,
F. Matzkies,
B. Bartok,
L. Ye,
...
Ying Guo,
Chantal Tasset,
J. Sundy,
A. Jahreis,
M. Genovese,
N. Mozaffarian,
R. Landewé,
S. Bae,
E. Keystone,
P. Nash
|
7 |
2021 |
7
🐜
|
|
🐜
|
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
17 auth.
P. Mease,
L. Coates,
P. Helliwell,
M. Stanislavchuk,
Anna Rychlewska-Hańczewska,
A. Dudek,
W. Abi-Saab,
Chantal Tasset,
L. Meuleners,
Pille Harrison,
...
R. Besuyen,
A. V. D. Aa,
N. Mozaffarian,
Joy M. Greer,
R. Kunder,
F. Bosch,
D. Gladman
|
7 |
2018 |
7
🐜
|
|
🐜
|
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo‐controlled trial with a re‐treatment extension
7 auth.
K. Reich,
J. Ortonne,
A. Gottlieb,
I. Terpstra,
G. Coteur,
Chantal Tasset,
...
P. Mease
|
7 |
2012 |
7
🐜
|
|
🐜
|
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
7 auth.
F. Namour,
P. Diderichsen,
E. Cox,
B. Vayssiere,
A. Van der Aa,
Chantal Tasset,
...
G. van't Klooster
|
6 |
2015 |
6
🐜
|
|
🐜
|
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
19 auth.
R. Westhovens,
W. Rigby,
D. M. van der Heijde,
D. Ching,
W. Stohl,
J. Kay,
A. Chopra,
B. Bartok,
F. Matzkies,
Z. Yin,
...
Ying Guo,
Chantal Tasset,
J. Sundy,
A. Jahreis,
N. Mozaffarian,
O. Messina,
R. Landewé,
T. Atsumi,
G. Burmester
|
6 |
2021 |
6
🐜
|
